Close Menu

NEW YORK – Molecular diagnostics company Biocartis reported on Thursday that it saw an expansion of its installed instruments base in the third quarter, with the US market representing 40 percent of new Idylla instrument placements.

The company also reported a 27 percent year-over-year increase in commercial cartridge volumes, predominantly driven by Europe and rest-of-world markets, and said the development of its liquid biopsy Idylla ctEGFR Mutation Assay during Q3 resulted in the test's launch on Oct. 25.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.